Drug List for Cardiology/Vascular Diseases
Description: Diseases having to do with the structure and function of the heart and blood vessels. Studies in these areas include: heart failure, coronary artery disease, high cholesterol, blood clots, circulation disorders, and others.
Below the search box are the FDA approved drugs for the Cardiology/Vascular Diseases category. Click any link to view the full drug information.
 | |
|
1. Phrase: 2. Area: |
|
|
3. Letter: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z |
|
| 4. Show all | |
Results: 84
Back to top
FDA Approved Listings:
The rules of principle for evaluating MediLexicon's FDA Approval Listings adhere to the FDA definitions of a new drug approval or a new molecular entity, and the Tufts Center for the Study of Drug Development.
MediLexicon's FDA Approved Drugs Listings include:
New Molecular Entities (NME): these NME's are described as a medication containing an active substance that have never previously approved in the US for marketing in any manner, shape or form (as defined by the FDA). In addition to this, there is also the inclusion of some FDA's Center for Drug Evaluation and Research (CDER) approved recombinant proteins and biologics.
MediLexicon's FDA Approved Drugs Listings do NOT include:
Over-the-counter products, diagnostic agents, generics, most vaccines, medical devices, biologic compounds (not approved by CDER), as well as new indications and new administrations of previously-approved compounds and new dosages.
Please note that the extra search boxes at the top of the website link to external drug website databases. In no event shall MediLexicon International Ltd be responsible for the content, accuracy or opinions expressed in these web sites.
The Cardiology/Vascular Diseases FDA drug information used in this section is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
